The Latest Breaking News from CGC

Discover three cannabis stocks with significant growth potential, and learn why analysts favor these names over Canopy Growth.

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in SNDL Inc. (SNDL) and Canopy Growth (CGC) now? Keep reading….

CGC has nearly tripled since late August - and now these three marijuana stocks have more upside potential, according to Wall Street.

Canadian cannabis producer Canopy Growth (CGC) reiterated ongoing concerns about its loss-making status. While the company is making significant efforts to return to profitability, is the stock worth buying now? Read on.

The pharma industry is poised for long-term growth supported by increasing demand for drugs worldwide and technological advancements. While leading pharma stocks Collegium Pharmaceutical (COLL) and Canopy Growth (CGC) should benefit from the industry tailwinds, let us determine which is the better buy.

The annual Crap Games Competition has been bringing Spectrum fans together for more than 25 years. It all began with an April fool’s joke in a magazine called Your Sinclair …

Although the cannabis industry shows long-term growth potential, its near-term performance is hampered by intense regulations and limited financing. So, let's analyze whether you should Buy, Hold or Sell cannabis stocks SNDL (SNDL) and Canopy Growth (CGC).

Canadian cannabis producer Canopy Growth (CGC) is making significant changes to its business model in an effort to turn profitable. However, given the regulatory challenges, will the company get success anytime soon? Let’s look at some of CGC’s metrics to understand if this penny stock is worth buying now.

The ideology champions the same tired policies that big government types predictably propose whenever they see something they don't like.

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

The cannabis industry faced several challenges last year, including overproduction amid high inflation weighing on overall demand. With growing concerns over rising inflation and a looming recession, the industry is expected to remain under immense pressure this year. So, it could be wise to avoid fundamentally weak cannabis stocks Tilray…